Cancer, Neurological & Lung Diseases are all Inflammatory Disorders

Learn how you can help battle Inflammation

PhorMed's lead technology, RP-323, is a cell repair therapy that helps the body repair itself

What we do

Discovering new approaches to therapy in the field of genomic medicine.

About Us

We are a biopharmaceutical company focused on the development and commercialization of RP-323, a targeted gene repair, immunotherapy, and stem cell activator for treating neurological diseases, blood disorders, and such inflammatory disorders as ARDS (Adult Respiratory Distress Syndrome).

Read More


We are happy to announce that you can now be part of this exciting technology and help make a difference by investing in PhorMed.


Invest Now

Science and Technology

RP-323 treats diseases upstream where issues start. It has the ability to add a needed phosphate to a pathway, turning the switch on/off inside the DNA, allowing proper DNA transcription and protein expression.


Read More


After multiple clinical studies RP-323 has been found to be safe and the company is now prepared to enter into the next phase of clinical trials advancing its pipeline in collaboration with two clinical sites in Atlanta Georgia.

Read More


PhorMed Inc is committed to good corporate citizenship. Our policy is to conduct our business affairs honestly and ethically.


Phormed Receives $700,000 from Angel Investor

On August 14, 2022, the company received a generous investment of $700,000 from one investor through a private placement. He purchased shares at $1.00 and received 20% bonus shares, 700,000 shares and 140,000 shares, respectively, totaling 840,000 shares.
Read More


Phormed Announces Results from On-Going ARDS Study

On August 3, 2022, PhorMed published a press release regarding our on-going Acute Respiratory Distress Syndrome study.

You can read the press release at

Read More


PhorMed Announces ARDS Study Results

PhorMed Inc, a Nevada Corporation (“PhorMed” or the “Company”), is a privately held clinical stage biopharmaceutical company. The Company’s study drug RP-323 is in an on-going acute respiratory distress syndrome (ARDS) study. ARDS is a lung disorder where fluid collects in the air sacs of the lungs, depriving organs of oxygen. These studies have generated positive results showing RP-323 significantly reduces the influx of inflammatory cells into the lungs thereby limiting damage to the lungs.
Read More